SCHEMBL30130532

SCHEMBL30130532

CC[C@H](C)[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O)[C@@H](C)CC)[C@@H](C)CC

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAGI3 Q5TCQ9 1/20 0.54
▸ EDNRA P25101 1/20 0.53
▸ KMT2A Q03164 1/20 0.51
▸ L3MBTL1 Q9Y468 1/20 0.51
▸ NPY1R P25929 3/20 0.50
▸ NPY2R P49146 3/20 0.50
▸ NPY4R P50391 3/20 0.50
▸ ACE P12821 2/20 0.50
▸ PRMT1 Q99873 1/20 0.50
▸ CASP1 P29466 1/20 0.49
▸ CASP3 P42574 1/20 0.49
▸ CASP4 P49662 1/20 0.49
▸ CASP5 P51878 1/20 0.49
▸ CASP7 P55210 1/20 0.49
▸ CASP9 P55211 1/20 0.49
▸ CASP6 P55212 1/20 0.49
▸ CASP8 Q14790 1/20 0.49
▸ CASP10 Q92851 1/20 0.49
▸ ERAP2 Q6P179 3/20 0.49
▸ ERAP1 Q9NZ08 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30092978 0.98 EDNRA (0.55) MAGI3EDNRAKMT2AL3MBTL1NPY1R
SCHEMBL29800257 0.96 GHSR (0.52) MAGI3EDNRANPY1RNPY2RNPY4R
SCHEMBL30130573 0.96 EDNRA (0.59) MAGI3EDNRANPY1RNPY2RNPY4R
SCHEMBL30093068 0.95 MAGI3 (0.54) MAGI3EDNRAKMT2AL3MBTL1NPY1R
SCHEMBL30093012 0.95 MAGI3 (0.54) MAGI3EDNRAKMT2AL3MBTL1NPY1R
SCHEMBL30130527 0.95 MAGI3 (0.54) MAGI3EDNRAKMT2AL3MBTL1NPY1R
SCHEMBL30093082 0.95 EDNRA (0.60) MAGI3EDNRAERAP2ERAP1KISS1R
SCHEMBL30093065 0.94 EDNRA (0.57) MAGI3EDNRAERAP2KISS1RRXFP4
SCHEMBL30130554 0.94 EDNRA (0.57) MAGI3EDNRAERAP2KISS1RRXFP4
SCHEMBL30130551 0.93 KISS1R (0.54) MAGI3NPY1RNPY2RNPY4RACE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230287044-A1 NOVEL ANTIBACTERIAL PEPTIDE AND USE THEREOF ANYGEN CO., LTD. (KR) 2023-09-14 — — US claimed
EP-4129064-A1 NOVEL ANTIBACTERIAL PEPTIDE AND USE THEREOF Anygen Co., Ltd. (KR) 2023-02-08 — — EP claimed
US-20230287044-A1 NOVEL ANTIBACTERIAL PEPTIDE AND USE THEREOF ANYGEN CO., LTD. (KR) 2023-09-14 — — US disclosed
EP-4129064-A1 NOVEL ANTIBACTERIAL PEPTIDE AND USE THEREOF Anygen Co., Ltd. (KR) 2023-02-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230287044-A1 NOVEL ANTIBACTERIAL PEPTIDE AND USE THEREOF VIP, CUTA, LNPEP MAGI3 2439/4885EDNRA 3344/4885KMT2A 3301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback